Please use this identifier to cite or link to this item:
https://hdl.handle.net/1/3070| Title: | Polatuzumab, Bendamustine & Rituximab (Pola-Br) Efficacy in Relapsed/Refractory Diffuse Large B Cell Lymphoma (Rrdlbcl) Trial-Ineligible Patients: An Australian Lymphoma Registry (Lardr) Study | Authors: | Shaw, B;Chung, E;Wellard, C;Yoo, E;Bennett, R;Birks, C;Johnston, A;Cheah, C;Hamad, N;Simpson, J;Barraclough, A;Ku, M;Viiala, N;Ratnasingam, S;Armytage, Tasman ;Cochrane, T;Chong, G;Lee, D;Manos, K;Keane, C;Wallwork, S;Opat, S;Hawkes, E A | Affliation: | Central Coast Local Health District Gosford Hospital |
Issue Date: | 1-Aug-2023 | Department: | Pathology | Abstract: | HemaSphere. Conference: EHA2023 Hybrid Congress. Frankfurt Germany. 7(Supplement 3) (pp 2308-2309), 2023. Date of Publication: 01 Aug 2023. | URI: | https://hdl.handle.net/1/3070 | Publicaton type: | Conference Abstract | Keywords: | Cancer Drug Therapy |
| Appears in Collections: | Health Service Research |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.